Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cinnarizine/dimenhydrinate - Hennig Arzneimittel GmbH

Next Previous
X
Search
Drug Profile

Cinnarizine/dimenhydrinate - Hennig Arzneimittel GmbH

Alternative Names: Arlevert; Dimenhydrinate/cinnarizine - Hennig Arzneimittel GmbH

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hennig Arzneimittel GmbH
  • Class Amines; Antihistamines; Benzhydryl compounds; Piperazines; Purines; Vestibular disorder therapies
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Vertigo

Most Recent Events

  • 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
  • 28 Feb 2023 Chemical structure information added
  • 16 Feb 2023 Launched for Vertigo in Finland, Ukraine, Switzerland, Germany, Hungary, Sweden, Sweden, Czech Republic, Netherlands, Portugal, Ireland, Austria, Poland, Denmark and United Kingdom (PO) subsequently launched before February 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top